$IBRX
ImmunityBio, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$7.92
▲+2.65%+$0.205
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateImmunityBio, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is IBRX up today? It is at $7.92 (+2.65%), and our scanner flagged it 180 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment IBRX spikes, and full due diligence on IBRX — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $IBRX 180 times in the last 30 days. Create a free account to track $IBRX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on IBRX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for IBRX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystImmunityBio, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingSC 13D/AActivist 5%+ stake updatedAug 6, 2026 · 37 days agoAcross every filing on file, supply equal to 301.3% of the tradeable float is in play - 301.3% more can still be issued.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
202,631,048 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $460.0M in size · Priced at $2.27/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Cohen Cheryl Director | Sold (automatic/other) | -131K 0.01% of company | sold 51% | 125K | $1.2M at $9.50 | Jul 2, 26 |
Cohen Cheryl Director | Other | 56K | added 28% | 257K | $167K at $2.98 | Jul 2, 26 |
Selecky Christobel Director | Sold (automatic/other) | -159K 0.02% of company | n/a | n/a | $1.4M at $9.02 | Jul 1, 26 |
Selecky Christobel Director | Other | 159K 0.02% of company | n/a | 159K | $475K at $2.98 | Jul 1, 26 |
Selecky Christobel Director | Sold (automatic/other) | -1K | n/a | n/a | $9K at $9.00 | Jun 30, 26 |
Selecky Christobel Director | Other | 1K | n/a | 1K | $3K at $2.98 | Jun 30, 26 |
Selecky Christobel Director | Sold (automatic/other) | -96K | n/a | n/a | $862K at $9.01 | Jun 29, 26 |
Selecky Christobel Director | Other | 96K | n/a | 96K | $272K at $2.84 | Jun 29, 26 |
Simon Barry J. Director | Sold (automatic/other) | -25K | sold 0.9% | 2.80M | $197K at $7.88 | Jun 24, 26 |
Simon Barry J. Director | Sold (automatic/other) | -23K | sold 0.8% | 2.83M | $165K at $7.18 | Jun 4, 26 |
Soon-Shiong Patrick Officer | Acquired (grant/award) | +4.61M 0.4% of company | added 0.7% | 624.85M | $25.0M at $5.43 | Mar 31, 26 |
Simon Barry J. Director | Sold (automatic/other) | -75K | sold 2.6% | 2.85M | $901K at $12.01 | Feb 24, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on IBRX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for IBRX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
IBRX last traded at $7.92, up 2.65% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
ImmunityBio, Inc. Common Stock (IBRX) is next expected to report earnings on Tuesday, November 3, 2026, about 51 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The IBRX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged IBRX 180 times in the last 30 days.
IBRX (ImmunityBio, Inc. Common Stock) trades on XNAS, with a market cap of about $8.38B in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge IBRX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$IBRX discussion
Sign in to ask a question or join the discussion.